Angiogenesis and inflammation are clearly interconnected and interdependent processes that are dysregulated in a series of systemic and brain pathologies. Herein, key aspects regarding endothelial cell function and tissue remodelling that are particularly affected or aggravated by inflammation are presented. Most importantly, the cellular and molecular mechanisms involved in the vascular regulation of the inflammatory processes occurring in several brain disorders and how they impact on disease/injury progression are detailed, highlighting potential targets for therapy. Finally, nanomedicine-based approaches designed to overcome limitations pertaining to low systemic bioavailability, light, pH and temperature sensitivity and/or rapid degradation of these targets, and to optimize their mode of action are discussed. Ultimately, we expect this review to provide new insight and to suggest novel approaches for the treatment of blood-brain barrier dysfunction per se or as a means to treat the injured or diseased central nervous system.
The endothelium constitutes a metabolically active cellular layer surrounding the lumen of blood and lymphatic vessels. Together with a supporting layer of pericytes and glia, endothelial cells are part of a highly selective blood-brain barrier (BBB) that is dedicated to maintain vascular homoeostasis, to regulate vascular constriction/relaxation and blood cell trafficking across the brain parenchyma (Aird 2007; Park and Park 2015) . Nevertheless, the endothelium does not normally interact with circulating blood cells. In fact, resting endothelial cells inhibit the expression of molecules, such as E-selectin, vascular cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1), on their cell surface to prevent blood cell adhesion. Conversely, the activated endothelium can expose P-selectin (otherwise stored in Weibel-Palade bodies) as a warning sign for inflammation and/or injury. These secretory vesicles also function as storage units for von Willebrand factor, a glycoprotein involved in blood coagulation (Pober and Sessa 2007) . Additionally, endothelial cells conceal signals that promote activation, adhesion and accumulation of platelets by producing both nitric oxide (NO) and prostaglandin I2 (PGI2; also known as prostacyclin), therefore preventing blood coagulation. Blood fluidity is also maintained by endothelial expression of tissue factor pathway inhibitors, heparan sulphate proteoglycans, thrombomodulin and activated protein C (van Hinsbergh 2012). The brain vasculature interacts with a multitude of cellular types that, among other functions, secrete a series of inflammatory mediators and growth factors required for vascular growth and maintenance (Aird 2007; Pober and Sessa 2007) (Fig. 1 ). For instance, mast cells store molecules, such as histamine (vasodilator) and heparin (anticoagulant), in their intracellular granules, which regulate blood fluidity (Kunder et al. 2011) . Perivascular macrophages and parenchymal microglia are responsible for the release of factors that enable vascular vessel formation (Sumi et al. 2010; Rymo et al. 2011) . The endfeet of astrocytes respond to endothelial activation and dysfunction by producing molecules that change vascular permeability and tone (Abbott et al. 2006) . Distinct T-cell subsets, CD8 + T cells in particular, can infiltrate the different barriers of the CNS, including the blood-leptomeningeal barrier. In a neuroinflammatory microenvironment, the barrier composed by the parenchymal basement membrane and astrocytic feet (glia limitans) is breached by T cells and antigen presentation cells unfold a signalling cascade that recruits more immune cells (Engelhardt and Ransohoff 2012) . Lastly, recent data have suggested that endothelial cells have essential roles in regulatory mechanisms of immune response (e.g. immunoglobulin recycling via endothelial FcRn receptors, ability to express Major histocompatibility complex I and II and to function as antigen presentation cells to T cells) (Mai et al. 2013; Shuvaev et al. 2015) . Herein, we detail the mechanisms involved in endothelial dysfunction and neuroinflammation, emphasising targets for nanomedicine-based therapy.
Endothelial activation and dysfunction in brain disorders
Vascular dysregulation can significantly impact the inflammatory milieu and impair repair. In simple terms, endothelial cells can undergo two types of activation: fast and independent of gene expression (type I), which activates calcium signalling pathways, or slower and gene expression-dependent (type II), which induces pro-inflammatory pathways (Hainsworth et al. 2015) . This process promotes vascular leakage of plasma proteins by opening intercellular junctions, and bolsters lymphocyte and macrophage infiltration through a more deregulated and permeable endothelium (Majno 1998; Griffioen and Molema 2000) . The most relevant endothelial cell-derived inflammatory mediators (Fig. 2) , and their role in brain disease, will be detailed in the next section. Table 1 contains information on current clinical trials focusing on the correlation between neuroinflammation and vascular repair.
Matrix metalloproteinases (MMP)
These secreted or membrane-bound calcium-and zincdependent proteolytic endopeptidases are typically responsible for degrading extracellular matrix (ECM) components, remodelling tissue, and regulating endothelial cell migration and leukocyte extravasation (Wang et al. 2006; Goldman and Chen 2011) . Alternatively, MMP may exert their action on non-matrix substrates [e.g. interleukin-1beta (IL-1b), vascular endothelial growth factor-A (VEGF-A), stromal cell-derived factor-1, tumour necrosis factor alpha (TNF-a)] regulating their bioavailability and affecting the outcome of the inflammatory process (Nissinen and Kahari 2014) . In The endothelium interacts with cells circulating in the bloodstream (e.g. macrophages, leucocytes, mast cells, platelets) but also with cells present in the brain parenchyma (e.g. astrocytes, microglia, pericytes). This complex set of interactions and the molecules that are produced regulate and interfere with vascular activity, blood flow and brain parenchyma homoeostasis. ATP, adenosine triphosphate; ICAM-1, intercellular adhesion molecule-1; IL, interleukin; NGF, nerve growth factor; NO, nitric oxide; O2-, superoxide; ONOO-, peroxynitrite; PG, prostaglandin; PDGF, platelet-derived growth factor; TNF-a, tumour necrosis factor alpha; VCAM-1, vascular cell adhesion molecule-1; VEFG, vascular endothelial growth factor; vWF, von Willebrand factor. recent years, the role of MMP-9 has been explored in multiple sclerosis (MS). The cerebrospinal fluid and serum MMP-9 levels from patients positively correlated with the degree of BBB disruption , and the combined administration of IFN-b with doxycycline (MMP inhibitor) resulted in reduced blood levels of MMP-9 and lesion activity (Minagar et al. 2008) . Recently, the role of MMP-9 on brain pathology was reviewed, and the apparent conflicting effect of this enzyme was noted (Vafadari et al. 2015) . MMP-9 has opposing contributions in the pathogenesis and recovery process of stroke (Rivera et al. 1997; Jin et al. 2010) , and while MMP-9 knockout mice display behavioural impairment (Ethell and Ethell 2007) , they are more resistant to motor deficits (traumatic brain injury) (Wang et al. 2000) , show lower numbers of activated microglia and higher amounts of dopaminergic neurons (murine and monkey models of Parkinson's disease, PD) (Annese et al. 2015) . In fact, patients with traumatic brain injury (TBI) have their ventricular cerebrospinal fluid enriched in MMP-3 and MMP-9, which may potentiate Fig. 2 Overview on the type of molecules produced by the endothelium and their main function. Examples of key molecules are provided below each category (reactive oxygen species, metalloproteinases, cytokines and chemokines, growth factors, pro-coagulant protease, prostaglandins, and adhesion molecules) and above the process they regulate. H2O2, hydrogen peroxide; ICAM-1, intercellular adhesion molecule-1; IL, interleukin; MMP, metalloproteinases; NGF, nerve growth factor; O2-, superoxide; PG, prostaglandin; VEFG, vascular endothelial growth factor. BBB opening and haemorrhage (Grossetete et al. 2009; Sashindranath et al. 2012) . Moreover, although endogenous MMP-9 may have amyloid-degrading capability, knockout mice are resistant to memory impairment induced by Ab40 [Alzheimer's disease (AD)] (Nalivaeva et al. 2008; Mizoguchi et al. 2009 ). MMP activity can be easily neutralized by tissue inhibitors of metalloproteinase (Griffioen and Molema 2000) , but these molecules can exercise both pro-and antiinflammatory actions. This dual effect poses a significant challenge for the development of an efficient therapy targeting inflammatory and/or vascular diseases. To conclude, endothelial cells activated by recombinant human erythropoietin can secrete MMP, namely MMP-2 and MMP-9, which promotes neural progenitor cell migration (Wang et al. 2006) . In that sense, targeting specific MMP could be helpful for the development of more comprehensive neural repair strategies.
Growth factors
The release of growth factors initiates vital processes such as cell growth and migration, vascular remodelling and endothelial permeability (Su 2015) . Basic and acidic fibroblast growth factor, insulin-like growth factors, transforming growth factor-beta (TGF-b), platelet-derived growth factor and its subfamily of vascular endothelial growth factors are among the most well described molecules that regulate vascular function. For instance, VEGF-A promotes vasodilation indirectly via endothelial NO production. After injury, it mediates processes such as proliferation, migration and differentiation of endothelial cells and its rapid increase leads to recruitment of bone marrow-derived endothelial progenitor cells to the lesion site to promote neovascularization (Zampetaki et al. 2008 ). Additionally, VEGF-A stimulates the production of cytokines and the expression of surface adhesion molecules by endothelial cells, which facilitates a peripheral immune cell response (Angelo and Kurzrock 2007) . Interestingly, levodopa (L-DOPA) causes VEGF-A up-regulation by astrocytes in close contact with blood vessels of animals with L-DOPA-induced dyskinesia (involuntary muscle movements). Higher VEGF-A messenger RNA levels were also found in dyskinetic versus nondyskinetic PD patients (Ohlin et al. 2011) . Endothelial dysfunction in PD may result from chronic L-DOPA treatments (Yoon et al. 2014) and even acute administration increases regional cerebral blood flow and BBB permeability (Ohlin et al. 2012) . Others have observed the deleterious effects of VEGF-A. Namely, cortex injection of this growth factor disrupted claudin-5 and occludin expression resulting in BBB breakdown (Argaw et al. 2009 ). Later on, the same group reported that the source of VEGF-A was astrocytic and that blocking this signalling pathway could ameliorate injury and symptoms present in demyelination lesions and in murine MS models respectively (Argaw et al. 2012) . In parallel, CD8 + T cells are also able to induce the expression of VEGF-A by neurons in an inflammatory context, potentiating the increase in BBB permeability (Suidan et al. 2010) . Another example is TGF that contributes to quiescent vessel formation, ECM production and cell growth maintenance (Griffioen and Molema 2000) . Angiopoietins are another group of factors that have a crucial role in establishing communication between the endothelium and the surrounding mesenchyme (Griffioen and Molema 2000; Fagiani and Christofori 2013) . Angiopoietin (Ang)-1 and Ang-2 are ligands for receptor tyrosine kinase Tie-2, which is mainly expressed by endothelial cells. Ang-1/Tie-2 binding blocks the expression of inflammatory genes, promotes vessel integrity and is responsible for inhibiting vascular leakage. Ang-1 is expressed by vascular smooth muscle cells, fibroblasts and pericytes while Ang-2 is stored in WeibelPalade bodies (WBP) and is only present at sites of vascular remodelling (Fiedler et al. 2004; Wakui et al. 2006) . The roles of Ang-3 (mouse-specific) and Ang-4 (human-specific) are not fully disclosed but they act, respectively, as an antagonist and agonist of tyrosine kinase signalling (Valenzuela et al. 1999) . Thus, continuing research and characterization of vascular growth factors and their signalling cascades constitute a great therapeutic opportunity to further refine the available therapeutic approaches.
Thrombin
This protease potentiates oxidative stress in brain endothelial cells and activates neighbouring glial cells inducing their expression of IL-6, IL-1b and TNF-a (Choi et al. 2005b; Zundorf and Reiser 2011; Alabanza and Bynoe 2012) . In this sense, the administration of direct thrombin inhibitors has been proposed as a means to reduce neuroinflammation and vascular expression of inflammatory proteins. A significant increase in cell survival, a decrease in reactive oxygen species (ROS) levels and in hypoxia-mediated inflammatory gene expression (IL-6, HIF-1a, MMP-2 and CCL2) were reported in transgenic AD mice treated with dabigatran, an anticoagulant direct thrombin inhibitors (Tripathy et al. 2013) . The neurotoxic effect of thrombin has been described for AD and PD (Choi et al. 2005a; Yin et al. 2010) . Moreover, thrombin and endothelial microparticles (membrane vesicles originated from activated or apoptotic endothelium) were found to potentiate vascular permeability and leukocyte infiltration in MS (Marcos-Ramiro et al. 2014) . Finally, thrombomodulin, a cell transmembrane glycoprotein, is a crucial cofactor for thrombin, shifting thrombin activity towards an anticoagulant effect (Boehme et al. 1996) . Thrombomodulin, and the fibrinolytic activity of tissue plasminogen activator (tPA), is inhibited by astrocytic TGF-b-induced up-regulation of plasminogen activator inhibitor-1 (Tran et al. 1999) . Therefore, the modulation of thrombin signalling constitutes a helpful strategy for the regulation of cerebrovascular development and inflammation.
Prostaglandins
Prostaglandins are lipid mediators, obtained from fatty acids, which are produced by the majority of cells, including the endothelium. These mediators, which have a protective function in the resolution of inflammation through (PGI2) and PGFa, inhibit vascular endothelial cell activation and stimulate intracellular 3 0 -5 0 -cyclic adenosine monophosphate production (Birukova et al. 2007 ). In addition, PGI2 also promotes vasodilation and inhibits platelet adhesion (Pober and Sessa 2007) . In summary, these mediators have a potential clinical relevance for the maintenance of blood fluidity and in response to pathogenic mechanisms.
Adhesion molecules
Under pathological conditions, the endothelium contracts, sheds epithelial-and endothelial-specific glycoproteins and exposes adhesion molecules (Shuvaev et al. 2015) . These typically include VCAM-1, ICAM-1, platelet/endothelial cell adhesion molecule, vascular endothelial (VE)-cadherin, P-and E-selectins. Selectins are responsible for facilitating adhesion between white blood cells and damaged endothelial cells. In epileptic patients, seizures induce an inflammatory cascade that up-regulates the expression of adhesion molecules by the endothelium, allowing the invasion of circulating immune cells and BBB disruption (Librizzi et al. 2007 (Librizzi et al. , 2012 . VCAM-1 and ICAM-1, produced by quiescent endothelial cells, are up-regulated in inflamed sites and in vascular pathologies; platelet/endothelial cell adhesion molecule is responsible for supporting leukocyte diapedesis (Vestweber 2015) . Another type of adhesion molecules are integrins, transmembrane protein receptors for ECM proteins, immunoglobulins or cell surface ligands by peptide sequences, composed by a and b subunits. Integrin a v b 3, expressed on normal resting endothelium, mediates cellular adhesion to laminin, fibrinogen, collagen, von Willebrand factor or osteopontin and plays a crucial role in angiogenesis (Griffioen and Molema 2000) . TNF-a and IL-8, among other factors, up-regulate its expression by endothelial cells, and for that reason, a v b 3 is typically found in inflamed tissue (Brooks et al. 1994) . Natalizumab (humanized monoclonal antibody against a4 integrin) was the best option for MS patients resistant to classic treatments with IFN-b or glatiramer acetate by preventing the attachment and passage of immune cells through the BBB (Kalincik et al. 2015) . Consequently, blocking or inhibiting the activity of adhesion molecules can show great potential for therapy.
Reactive oxygen species (ROS)
The unbalanced formation of ROS is a result of proinflammatory activation (Touyz and Briones 2011) . The most common species, superoxide anion and hydrogen peroxide, are crucial regulators of endothelial cell proliferation and death (Kim and Byzova 2014) . Recent data have shown that oxidative stress can also activate protective mechanisms directed at preventing cell damage and at neutralizing superoxide radicals and peroxides (Kim and Byzova 2014; Szewczyk et al. 2015) . In a context of chronic inflammation, oxidative stress activates several transcription factors such as nuclear factor kappa-light-chain-enhancer of activated B cells (NF-jB), activator protein-1 and peroxisome proliferatoractivated receptor gamma (Kim and Byzova 2014) . Similar to many inflammatory mediators, ROS generation is a complex process whose targeting may bring therapeutic advantages. Recently, edavarone, a free radical scavenger, was found to synergize with tPA to promote vascular reperfusion while decreasing oxidative stress, MMP activity and inflammation (Sun et al. 2014) . In this sense, ROS are considered crucial targets that impact vascular endothelial growth and activation.
Cytokines and chemokines
Cytokines and their subfamily of chemokines are small secreted proteins that can be released by the endothelium to attract white blood cells to tissue and mediate angiogenesis (Shuvaev et al. 2015) . Endothelial dysfunction mechanisms include several cytokines and chemokines [e.g. CXCL8 or IL-8, chemokine (C-X3-C motif) ligand 1 or fractalkine, CCchemokine ligand 2 or CCL2, also known as monocyte chemotactic protein 1]. Several antagonizing or blocking molecules for chemokines, including a CCL2 peptide antagonist, are being tested as putative anti-angiogenic and antiinflammatory agents (Speyer and Ward 2011) . Interleukins are also responsible for mediating the inflammatory response, and IL-1b, IL-6 and TNF-a, in particular, have a crucial role in the amplification of this cascade (Blake and Ridker 2001) . Post-mortem tissue (Mogi et al. 1994) , cerebrospinal fluid (Blum-Degen et al. 1995; Mogi et al. 1996) and blood samples (Hisanaga et al. 2001; Scalzo et al. 2009 ) from PD patients have long shown the presence of these markers. Patients display activated microglia in substantia nigra and higher levels of pro-inflammatory cytokines (e.g. IL-1b, TNF-a) and circulating (and infiltrating) T lymphocytes (Brochard et al. 2009 ). However, this mechanism is still not fully known. IFN-b has been used as therapy in MS since it can decrease endothelial microparticles release, prevent transendothelial migration and stabilize BBB endothelium integrity and function (Sheremata et al. 2006) . Hence, proand anti-inflammatory cytokines and chemokines and their associated cascades constitute a relevant research focus to mediate endothelial dysfunction.
Nanotechnological approaches
Several of the therapies directed at repairing the brain vasculature and at restoring an appropriate inflammatory milieu have met limited success. The majority of the molecules discussed above have low systemic bioavailability, are sensitive to light, pH and temperature changes and/or are rapidly degraded, compromising their efficacy. In that sense, nanomedicine-based approaches have become increasingly popular since their goal is to streamline delivery and to boost the therapeutic potential of a given molecule. These nanometre scale carriers have many advantages, namely they can be modified in terms of size, shape, surface composition or charge, and can adsorb, encapsulate or bind to a chemical or biological agent of interest (Saraiva et al. 2016) . Although nanoformulations present exciting prospects for the treatment (and diagnosis) of several disorders, they may face a significant hurdle in terms of biodistribution. For instance, intravenous administration may lead to preferential accumulation in highly vascularized organs, while the mononuclear phagocytic system (also known as the reticuloendothelial system) may sequester the circulating nanocarriers (Moghimi et al. 2001) . Also, the formulations themselves or the therapeutic agent designed to treat the brain may induce toxicity in other organs inducing, for example, nephrotoxicity). An additional challenge for vascular-targeted therapies is that the brain endothelium does not express exclusive cell markers, and most formulations are not designed to deliver their cargo or act on the endothelium itself. Therefore, we present approaches that were initially designed for the repair of systemic vessels and organs, on a vascular and inflammatory level, but that can also prove useful for the CNS.
Focus on vascular integrity and regeneration
Thrombin-sensitive peptide substrates were adsorbed onto the surface of iron oxide nanoworms to detect thrombin activity. These flexible and filamentous polymeric formulations were administered intravenously in animals subjected to thromboplastin-induced pulmonary embolism to determine their efficacy as urinary biomarkers. Authors showed differences in the detection of thrombin levels between healthy and thrombotic animals and a positive correlation with the amount of clots formed in the lungs (Lin et al. 2013) . Using a similar rationale, perfluorocarbon-core nanoparticles containing a thrombin inhibitor (d-phenylalanyl-l-prolyl-larginyl chloromethylketone) inhibited protease-activated receptor and NF-kB activation, which consequently impairs the transcription of pro-inflammatory genes. Importantly, authors obtained a reduction in pro-coagulant activity and a recuperation of the aorta endothelial barrier integrity in vivo (Palekar et al. 2016) . A common approach to treat weakened or narrowed arteries is through the placement of small mesh tube called stent. Epigallocatechin-3-gallate-conjugated gold nanoparticles were developed as an alternative approach to drug-coated stents, to prevent restenosis (narrowing of a blood vessel) in atherosclerotic coronary artery disease. Arterial wall thickening often occurs as a result of proliferation and migration of smooth muscle cells and accumulation of white blood cells. This formulation was shown to inhibit smooth muscle cell migration without compromising endothelial cell viability in vitro. Although no data was collected for cell proliferation, these nanoparticles showed potential for the maintenance of vascular wall integrity (Khoobchandani et al. 2016) . Statins, a class of cholesterol lowering drugs (e.g. simvastatin, atorvastatin, lovastatin), were primarily designed for reducing cardiovascular disease. Statin-loaded reconstituted high-density lipoprotein nanoparticles were shown to accumulate preferentially in atherosclerotic lesions. Moreover, 3 month infusion with this formulation (low dose) delayed plaque inflammation, while 1 week intravenous administration (high dose) impacted advanced atherosclerotic plaques (Duivenvoorden et al. 2014) . With the purpose of clearing blood clots, chitosancoated magnetic nanoparticles containing tPA were prepared to enable magnetic-guided thrombolysis. The formulation was tested in a rat embolic model and had a fivefold higher efficiency than the free agent . A similar approach was attempted with silica-coated magnetic nanoparticles (diameter of 60 nm) in an ex vivo thrombolysis model with approximately threefold higher efficacy (Chen et al. 2012) . Recently, the combination of tPA with streptokinase, a fibrinolytic agent, in silica-coated magnetic nanoparticles led to a greater reduction in blood clot lysis time (~40%) (Tadayon et al. 2015) . A substantial advantage of using magnetic nanoparticles is the ability to maintain them in place while the therapeutic agent is being released/acting, minimizing side effects and the concentration of effective doses (Akbarzadeh et al. 2012) . A variation of this method was tested employing magnetic nanoparticle-loaded eNOS-overexpressing endothelial cells to efficiently repair damaged blood vessels in a model of carotid artery injury (arterial wire denudation). Endothelial cells (1.0 9 10 5 ) were delivered via the external carotid artery (Vosen et al. 2016 ). An additional advantage to their work was the enabling of constant blood flow. We have recently tested the application of retinoic acidloaded polymeric nanoparticles on human endothelial progenitor cells. The purpose is to endow these cells with higher angiogenic ability so that they migrate to the lesioned vasculature and promote a more efficient repair. Retinoic acid loaded nanoparticles were shown to promote the survival and proliferation of ischaemic endothelial cells, to enhance endothelial-induced neuronal differentiation and most, importantly, they increased human endothelial progenitor cell proliferation . Additionally, PEGylated poly(alkyl cyanoacrylate) and Polylactic acid (PLA) nanoparticles were shown to quench the toxic forms of the Ab1-42 peptide from the systemic circulation, which could potentially advance AD treatment (Brambilla et al. 2012) . Ab1-42 removal was also attained with gold nanoparticles (Majzik et al. 2010) . By preventing Ab deposition on blood vessels, BBB disruption can be prevented, as discussed previously. In summary, a series of therapeutic platforms are being developed to preclude, manage and/or repair the endothelium as a means to normalize vascular function.
Focus on inflammatory mediators
During inflammation, bradykinin is produced and acts on endothelial and astroglial bradykinin B2 receptors and stimulates the release of IL-6 from astrocytes through NFjB activation. This leads to BBB opening, adenosine triphosphate production and prostaglandin release, which affect vascular tone and endothelial permeability (Schwaninger et al. 1999; Abbott et al. 2006) . Despite showing promising results in animal studies, bradykinin treatment has not led to reproducible results in clinical trials (Abbott et al. 2006) . Given its vasodilator properties, bradykinin-potentiating peptide-decorated chitosan nanoparticles were developed to enhance vascular permeability and to decrease interstitial fluid pressure in the tumour area to enhance drug penetration, i.e. a platinum(IV) compound that then converts to cisplatin, a chemotherapy agent . This approach could be tested in a context of vasogenic oedema to reduce endothelial swelling, and other drugs could be alternatively loaded to resolve inflammation and/or to promote vascular repair. However, aquaporins are membrane channels that form pores for water passage and their dysregulation is commonly associated to vasogenic oedema after stroke (Abbott et al. 2006) . Antisense oligonucleotides were encapsulated into chitosan nanoparticles conjugated with a monoclonal antibody for transferrin receptor-1 to counteract aquaporin activity (Kozlu et al. 2014) . These nanoparticles have not been tested in vivo but show significant therapeutic potential for stroke. Minocycline, another inflammatory mediator and vasodilator, regulates BBB disruption and alleviates neuroinflammation by inhibiting hypoxia-inducible factor 1a (HIF-1a) activity through SIRT-3/PHD-2 pathway (Yang et al. 2015) . Minocycline was complexed with Ca 2+ and bis(2-ethylhexyl) sulfosuccinate in poly(lactic-co-glycolic acid) nanoparticles. This synthesis process led to a stable drug release over the course of 30 days in artificial cerebrospinal fluid (Holmkvist et al. 2016) . Although poly(lacticco-glycolic acid) nanoparticles are associated with minimal systemic toxicity, the drug payload capacity of this polymer is low. Using a classical endotoxin model, polyethylene glycol (PEG)-coated gold nanoparticles were shown to decrease NO production by inhibiting NF-kB and IFN-c signalling in lipopolysaccharide (LPS)-stimulated macrophages (Ma et al. 2010) . The anti-inflammatory properties of gold nanoparticles and their low toxicity have been extensively reviewed elsewhere; their role in angiogenesis remains unclear and further studies are needed (Hornos Carneiro and Barbosa 2016) . The same in vitro model was used to demonstrate an anti-inflammatory effect by PGE1-loaded lipid nanoparticles (Gao et al. 2010) . To counteract IL-1 signalling, IL-1 receptor antagonist-poly(2-hydroxyethyl methacrylate)-pyridine nanoparticles were constructed and shown to be stable for several days and to efficiently block IL-1b signalling (Agarwal et al. 2015) . Similarly, a block copolymer efficiently bound IL-1receptor antagonist and had the same effect in a rat stifle joint maintaining a higher half-life than its soluble counterpart (~3 times more) (Whitmire et al. 2012) . Antiinflammatory therapy per se may be an overly simplistic approach since most inflammatory mediators are needed for normal vascular function. The key will be devising a platform that instead of depleting it, normalizes or counteracts excessive (deleterious) inflammation.
Focus on oxidative stress balance Oxidative stress also plays an important role in the inflammatory response. In this sense, some nanoparticles have been shown to display free radical scavenging activity, such as cerium oxide, gold or silver nanoparticles (Tsai et al. 2007; Dauthal and Mukhopadhyay 2012; Ramamurthy et al. 2013) . Currently, there are therapies focusing on polyphenols. These molecules reduce the production of inflammatory cytokines like TNF-a, IL-1b and prostaglandin E2 (Rubio-Perez and Morillas-Ruiz 2012). Particularly, AD patients treated with resveratrol (naturally occurring phenol) over the course of a year showed sustained cerebrospinal fluid and plasma Ab40 levels (compared to the placebo group) (Turner et al. 2015) . Resveratrol has shown anti-oxidant properties, and to bypass poor stability, resveratrol-loaded stearic acid-based nanoparticles coated with poloxamer 188 were synthesized and had approximately eight times higher oral bioavailability than the free phenol (Pandita et al. 2014) . Another group developed resveratrol-capped gold nanoparticles, which inhibited MMP-9 activity and the migration capacity of breast cancer cells (Park et al. 2016) . So, nanomaterials can provide the opportunity to deliver anti-oxidant molecules that act directly on inflammatory mediators (independently of their cellular origin) or that may modulate ECM properties.
Focus on ECM restitution
The tumour microenvironment is particularly enriched in MMP and other inflammatory mediators, which enable ECM degradation to accommodate cell growth and migration. Activatable low molecular weight protamine conjugated to PEG-poly(caprolactone) nanoparticles were loaded with paclitaxel, a chemotherapy agent, and were shown to significantly accumulate in MMP-expressing tumour cells. Nude animals that received C6 glioma cells intracranially and were treated with this formulation had a longer survival time (Gu et al. 2013) . Taking advantage of MMP over-expression in tumours, PEGylated iron oxide nanoparticles directed at CXCR4 and MMP-2/9 expressing cells were prepared and showed higher signal-enhancing ability by magnetic resonance in tumour-bearing mice (Gallo et al. 2014) . Gold nanoparticles stabilized by polyvinylpyrrolidone were also shown to significantly reduce MMP-8 and MMP-9 activity in murine macrophages (Hashimoto et al. 2015) . Laminin is one of the important targets of MMP-9-mediated degradation in MS (Oki et al. 2004) . Recently, nanowires were developed to adsorb up to four times more laminin to create a more efficient cell substrate (Hammarin et al. 2014) . These very thin needlelike structures may also be used to prevent ECM degradation. HIF-1a is a key molecule that leads to high vascular permeability and to the expression of vascular molecules (such as VEGF and MMP) that can ultimately be harmful to endothelial cells and tight junction integrity (Ogunshola & AlAhmad 2012 , Engelhardt et al. 2014 . Additionally, HIF-1a accumulates in hypoxic tumour microenvironments, where its over-expression promotes tumour growth and invasion. In that sense, siRNA silencing HIF-1a micellar nanoparticles were developed and were shown to inhibit tumour growth (Liu et al. 2012) . Indole-conjugated nanosilica and magnetic nanoparticles were also shown to reduce HIF-1a expression in a hepatoma cell line (Chen et al. 2014) . The ECM is a flexible supporting system that provides a means to either maintain homoeostasis or to fight tumour growth. Designing nanomaterials that regulate MMP activity and/or that ensure the maintenance of ECM constituents will offer great potential particularly for oncological treatments.
Conclusions
The endothelium offers a high degree of heterogeneity and complexity, owing to its diverse morphology, location and function. Vascular alterations are directly or indirectly involved in a wide variety of human disorders and several inflammatory mechanisms are triggered by and contribute to the progression of endothelial dysfunction. This interplay can deeply affect other cellular types, in physiological or pathological conditions, impacting neurogenesis, neural survival and regeneration. Traditionally, nanoformulations are conceived to cross the BBB in order to treat the injured brain parenchyma. Hence, the repair of the brain vasculature per se is often neglected in spite of its therapeutic potential. We expect this review to provide new insight on disease mechanisms and novel nanomedicine-based therapies with endothelium-protective properties that may also benefit the lesioned and/or injured CNS.
